Allogene Therapeutics, Inc. · NASDAQ:ALLO

Allogene Therapeutics — AACR Annual Meeting 2023

14 slides from Allogene Therapeutics's conference presentation, April 2023

  1. Slide 1: TRAVERSE: A phase 1 multicenter study evaluating the safety and efficacy of ALLO-316 in ccRCC

    TRAVERSE: A phase 1 multicenter study evaluating the safety and efficacy of ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) Samer A Srour, MD1; Ritesh Kotecha, MD2; Brendan Curti, MD3; Jad Chahoud, MD4; Alexandra Drakaki, MD, PhD5; Lily Tang, PhD 6; Lovely Go

  2. Slide 2: TRAVERSE: First-in-Human Trial of Allogeneic Anti-CD70 CAR T Candidate for RCC

    TRAVERSE: First-in-Human Trial of Allogeneic Anti-CD70 CAR T Candidate for RCC  Relapsed and refractory RCC represents high unmet need • Large patient population with poor survival outcomes1-3 • Limited effective therapeutic options after failure of immune checkpoint inhibitors (ICIs) and tyrosine

  3. Slide 3: TRAVERSE: Study Design and Objectives

    TRAVERSE: Study Design and Objectives • Phase 1 multicenter, dose-escalation study, exploring two conditioning regimens and 4 cell dose levels (DLs) Conditioning Regimen FCA FC Dose Regimen DL1 DL2 DL3 DL4 Fludarabine (F) 30 mg / m2 daily x 3 Cell Dose 40 x 106 80 x 106 120 x 106 240 x 106 Cyclophos

  4. Slide 4: TRAVERSE: Patient Demographics and Disposition

    TRAVERSE: Patient Demographics and Disposition  All patients had advanced or metastatic ccRCC Patients who received ALLO-316a and prior therapy ICI and TKI Demographic Data at Baseline (n=19) Age, median (range), yrs 62 (50, 70) Gender: Male / Female, % 84 / 16  Median time from enrollment to init

  5. Slide 5: ALLO-316: Safety and Tolerability

    ALLO-316: Safety and Tolerability  Toxicity Patients who received ALLO-316 (n=19) • The safety profile is overall comparable to what is seen All Grades Grade 3+ with autologous CAR T TEAEs of Interestb n (%) n (%) • One DLT event (Gr 3 type 2 autoimmune hepatitisa) in Infusion-Related Reaction 1 (5

  6. Slide 6: ALLO-316: Anti-Tumor Activity in CD70+ RCC

    ALLO-316: Anti-Tumor Activity in CD70+ RCC  Patients evaluable for efficacy (n=18): All Patients CD70+ Patients (n=18c) (n=10c) • ORR = 17%, DCR = 89% Response Ratesa ORRa, n (%) 3 (17) 3 (30)  Patients with CD70+ RCC (n=10): DCR, n (%) 16 (89) 10 (100) • 3/10 (30%) achieved PR • DCR = 100% H-Scor

  7. Slide 7: ALLO-316: Anti-Tumor Activity in CD70+ RCC

    ALLO-316: Anti-Tumor Activity in CD70+ RCC 100 CD70 Negative or Unknown (N=8) CD70 Positive (N=10) 80 Change from Baseline, BOR (%) 60 40 20 0 5% Reduction * * -20 30% Reduction -40 -60 PD SD -80 PR -100 * Confirmed PRs DL1 DL1 DL1 DL2 DL2 DL1 DL1 DL1 DL2 DL1 DL3 DL1 DL2 DL2 DL2 DL3 DL2 DL1 FCA FC F

  8. Slide 8: ALLO-316: Durable Disease Control in CD70+ RCC

    ALLO-316: Durable Disease Control in CD70+ RCC * PR SD PD Death Due to Disease Progression Death Not Attributed to Disease Progression Follow-up ongoing Re-Treatment Start Anti-Cancer Therapy Confirmed PR *Deepening response from D28 (27% reduction from baseline) to D56 (35% reduction from baseline)

  9. Slide 9: TRAVERSE Case Study 1: Deepening Response After Lowest Tested Cell Dose

    TRAVERSE Case Study 1: Deepening Response After Lowest Tested Cell Dose  68-year-old man with Baseline Month 1 Month 6 metastatic RCC to the lungs, refractory to multiple ICIs (ipilimumab, nivolumab, and pembrolizumab) and axitinib  Treated with FCA and ALLO- 316 40M CAR+ cells  Responded with in

  10. Slide 10: TRAVERSE Case Study 2: Primary Tumor Shrinkage in Patient With Stable Disease

    TRAVERSE Case Study 2: Primary Tumor Shrinkage in Patient With Stable Disease  70-year-old male with RCC metastatic to adrenal and bone, refractory to axitinib and pembrolizumab  Treated with FCA and 80M CAR+ cells  Best Overall Response of Stable Disease with 45% decrease in size of primary left

  11. Slide 11: Robust ALLO-316 CAR T Cell Expansion, Persistence and Tumor Trafficking

    Robust ALLO-316 CAR T Cell Expansion, Persistence and Tumor Trafficking ALLO-316 Detected in 3 of 4 ALLO-316 Expansion After Single-Dose Available Tumor Aspirates  High CAR T cell expansion was observed following both conditioning regimens and at relatively low cell doses; in peripheral blood, medi

  12. Slide 12: ALLO-316 Eliminates CD70+ Host T Cells, Preventing Allorejection and Supporting Persistence

    ALLO-316 Eliminates CD70+ Host T Cells, Preventing Allorejection and Supporting Persistence Day 4 Host T CAR T CD8 CD3 ALLO-316 CAR CD70 Day 10 Host T  Following ALLO-316 infusion, alloreactive host T cells upregulate CD70 by Day 4  ALLO-316 expands by Day 10 and eliminates CD70+ host T cells whil

  13. Slide 13: Summary: Preliminary Safety and Efficacy of ALLO-316 in Advanced RCC

    Summary: Preliminary Safety and Efficacy of ALLO-316 in Advanced RCC Off-the-shelf CAR T with encouraging anti-tumor activity and no unexpected safety signals  Treatment initiated with a median of 5 days from enrollment  Safety profile consistent with autologous CAR T  Anti-tumor activity in rela

  14. Slide 14: Thank You!

    Thank You! To our patients, their families and caregivers, & our clinical trial investigators and sites The CD70 ALLO CAR-T program, which utilizes Cellectis technology, is exclusively licensed from Cellectis by Allogene and Allogene holds global development and commercial rights.

Allogene Therapeutics — AACR Annual Meeting 2023 on 6ix